Evidence map›Paper›PMID 35534697›Full record

ArticleAAPS PharmSciTech2022

Optimization of DOTAP/chol Cationic Lipid Nanoparticles for mRNA, pDNA, and Oligonucleotide Delivery.

Mengwei Sun, Utkarsh J Dang, Yuhao Yuan, Alexandra Maria Psaras, Ositomiwa Osipitan, Tracy A Brooks, Fake Lu, Anthony J Di Pasqua

Open access · bronzeAbstract read
In one paragraph

Article in AAPS PharmSciTech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR-T Cell Engineering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Equip your vehicle for the right terrain: Using features of local pathology to guide engineering of targeted drug delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Mengwei SunDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, NY, 13790, USA.
Utkarsh J DangDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, NY, 13790, USA.
Yuhao YuanDepartment of Biomedical Engineering, The Thomas J. Watson College of Engineering and Applied Science, Binghamton University, Binghamton, NY, 13902, USA.
Alexandra Maria PsarasDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, NY, 13790, USA.
Ositomiwa OsipitanDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, NY, 13790, USA.
Tracy A BrooksDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, NY, 13790, USA.
Fake LuDepartment of Biomedical Engineering, The Thomas J. Watson College of Engineering and Applied Science, Binghamton University, Binghamton, NY, 13902, USA.
Anthony J Di PasquaDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, NY, 13790, USA. dipasqua@binghamton.edu.ORCID http://orcid.org/0000-0001-6321-6990
Binghamton University · US

Funding

Low-Power Stimulated Raman Time-Lapse Microscope for Tracking Dynamics and Fate of Lipid Droplets in Glioma CellsR15GM140444 · NIGMS · STATE UNIVERSITY OF NY,BINGHAMTON · PI LU, FAKE · 2020 to 2020
$433k
NIGMS NIH HHS R15 GM140444
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) can be used as delivery vehicles for nucleic acid biotherapeutics. In fact, LNPs are currently being used in the Pfizer/BioNTech and Moderna COVID-19 vaccines. Cationic LNPs composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)/cholesterol (chol) LNPs have been classified as one of the most efficient gene delivery systems and are being tested in numerous clinical trials. The objective of this study was to examine the effect of the molar ratio of DOTAP/chol, PEGylation, and lipid to mRNA ratio on mRNA transfection, and explore the applications of DOTAP/chol LNPs in pDNA and oligonucleotide transfection. Here we showed that PEGylation significantly decreased mRNA transfection efficiency of DOTAP/chol LNPs. Among non-PEGylated LNP formulations, 1:3 molar ratio of DOTAP/chol in DOTAP/chol LNPs showed the highest mRNA transfection efficiency. Furthermore, the optimal ratio of DOTAP/chol LNPs to mRNA was tested to be 62.5 µM lipid to 1 μg mRNA. More importantly, these mRNA-loaded nanoparticles were stable for 60 days at 4 °C storage without showing reduction in transfection efficacy. We further found that DOTAP/chol LNPs were able to transfect pDNA and oligonucleotides, demonstrating the ability of these LNPs to transport the cargo into the cell nucleus. The influence of various factors in the formulation of DOTAP/chol cationic LNPs is thus described and will help improve drug delivery of nucleic acid-based vaccines and therapies.

Indexed as

COVID-19NanoparticlesCationsCholesterolCOVID-19 VaccinesFatty Acids, MonounsaturatedHumansLiposomesOligonucleotidesPropaneQuaternary Ammonium CompoundsRNA, Messenger1,2-dioleoyloxy-3-(trimethylammonium)propaneCationsCholesterolCOVID-19 VaccinesFatty Acids, MonounsaturatedLipid NanoparticlesLiposomesOligonucleotidesPropaneQuaternary Ammonium CompoundsRNA, MessengerDOTAP/cholesterollipid nanoparticlesLNP-mRNAmRNA deliverytransfection efficiency

Identifiers

PMID35534697
PMCPMC9084260
OpenAlexW4229451525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.